Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT

From BugSigDB
Reviewed Marked as Reviewed by ChiomaBlessing on 2024-2-1
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI
Authors
Biagi E, Zama D, Nastasi C, Consolandi C, Fiori J, Rampelli S, Turroni S, Centanni M, Severgnini M, Peano C, de Bellis G, Basaglia G, Gotti R, Masetti R, Pession A, Brigidi P, Candela M
Journal
Bone marrow transplantation
Year
2015
Acute GvHD (aGvHD) is the main complication of hematopoietic SCT (HSCT) during the treatment of hematological disorders. We carried out the first longitudinal study to follow the gut microbiota trajectory, from both the phylogenetic and functional points of view, in pediatric patients undergoing HSCT. Gut microbiota trajectories and short-chain fatty acid production profiles were followed starting from before HSCT and through the 3-4 months after transplant in children developing and not developing aGvHD. According to our findings, HSCT procedures temporarily cause a structural and functional disruption of the gut microbial ecosystem, describing a trajectory of recovery during the following 100 days. The onset of aGvHD is associated with specific gut microbiota signatures both along the course of gut microbiota reconstruction immediately after transplant and, most interestingly, prior to HSCT. Indeed, in pre-HSCT samples, non-aGvHD patients showed higher abundances of propionate-producing Bacteroidetes, highly adaptable microbiome mutualists that showed to persist during the HSCT-induced ecosystem disruption. Our data indicate that structure and temporal dynamics of the gut microbial ecosystem can be a relevant factor for the success of HSCT and opens the perspective to the manipulation of the pre-HSCT gut microbiota configuration to favor mutualistic persisters with immunomodulatory properties in the gut.

Experiment 1


Reviewed Marked as Reviewed by ChiomaBlessing on 2024-2-1

Curated date: 2021/01/10

Curator: WikiWorks

Revision editor(s): WikiWorks, Chloe, ChiomaBlessing

Subjects

Location of subjects
Italy
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Graft versus host disease disease, graft-versus-host,disease, graft-VS-host,disease, homologous wasting,disease, runt,diseases, graft-versus-host,diseases, graft-VS-host,graft versus host disease,graft VS host disease,graft VS. host disease,graft-versus-host disease,graft-versus-host disease, resistance to,graft-versus-host disease, susceptibility to,graft-versus-host diseases,graft-versus-host-disease,graft-VS-host disease,graft-VS-host diseases,GVH,GVHD,GVHDS,homologous wasting disease,runt disease,Graft versus host disease
Group 0 name Corresponds to the control (unexposed) group for case-control studies
non-GvHD (Graft-versus-host disease)
Group 1 name Corresponds to the case (exposed) group for case-control studies
aGvHD (acute Graft-versus-host disease)
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
pre-HSCT (hematopoietic stem cell transplant) samples of subjects who underwent HSCT who developed acute graft-versus-host disease
Group 0 sample size Number of subjects in the control (unexposed) group
5
Group 1 sample size Number of subjects in the case (exposed) group
5
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
None.

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Roche454

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
Mann-Whitney (Wilcoxon)
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
Yes


Signature 1

Reviewed Marked as Reviewed by ChiomaBlessing on 2024-2-1

Curated date: 2021/01/10

Curator: William Lam

Revision editor(s): WikiWorks, Chloe, ChiomaBlessing

Source: Results (Text): Page 4, 3rd paragraph under sub-heading "aGvHD-associated gut microbiota signatures."

Description: Gut microbiota signatures in pre-HSCT samples of subjects who developed aGvHD compared to subjects who did not develop aGvHD (non-aGvHD)

Abundance in Group 1: decreased abundance in aGvHD (acute Graft-versus-host disease)

NCBI Quality ControlLinks
Bacteroidia

Revision editor(s): WikiWorks, Chloe, ChiomaBlessing

Signature 2

Reviewed Marked as Reviewed by ChiomaBlessing on 2024-2-1

Curated date: 2024/02/01

Curator: ChiomaBlessing

Revision editor(s): ChiomaBlessing

Source: Results (Text): Page 4, 3rd paragraph under sub-heading "aGvHD-associated gut microbiota signatures."

Description: Gut microbiota signatures in pre-HSCT samples of subjects who developed aGvHD compared to subjects who did not develop aGvHD (non-aGvHD)

Abundance in Group 1: increased abundance in aGvHD (acute Graft-versus-host disease)

NCBI Quality ControlLinks
Bacillota

Revision editor(s): ChiomaBlessing